Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Lung Neoplasms 6Carcinoma, Non-Small-Cell Lung 6Urinary Bladder Neoplasms 4Sarcoma, Alveolar Soft Part 3Carcinoma, Transitional Cell 3Breast Neoplasms 3Uterine Cervical Neoplasms 2Urethral Neoplasms 2Ureteral Neoplasms 2Squamous Cell Carcinoma of Head and Neck 2Ovarian Neoplasms 2Glioblastoma 2Gallbladder Neoplasms 2Fallopian Tube Neoplasms 2Extensive Stage Lung Small Cell Carcinoma 2Colorectal Neoplasms 2Cholangiocarcinoma 2Carcinoma, Renal Cell 2Triple Negative Breast Neoplasms 1Small Cell Lung Carcinoma 1Sarcoma, Clear Cell 1Sarcoma 1Rhabdoid Tumor 1Recurrent Bladder Urothelial Carcinoma 1Papillary renal cell carcinoma, sporadic 1Oropharyngeal Neoplasms 1Neoplasm Metastasis 1Nasopharyngeal Carcinoma 1Mouth Neoplasms 1Mesothelioma, Malignant 1

Interventions

atezolizumab 1Specimen Handling 1Magnetic Resonance Spectroscopy 1Immunoglobulin G 1Erlotinib Hydrochloride 1Disulfides 1Contrast Media 1Biopsy 1Bevacizumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
NIH × Papillary renal cell carcinoma, sporadic × atezolizumab × Clear all
NCT04981509 2026-06-03

Testing of Bevacizumab, Erlotinib, and Atezolizumab in Combination for Advanced-Stage Kidney Cancer

National Cancer Institute (NCI)

Phase 2 Recruiting
65 enrolled
Genitourinary

Hereditary leiomyomatosis and renal cell cancer, Papillary renal cell carcinoma, sporadic, Carcinoma, Renal Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡